Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Tuberculosis
100%
Interferon-gamma Release Assay
100%
Active Tuberculosis
100%
Prognostic Test
100%
T-SPOT.TB
69%
QFT-GIT
53%
Predictors of Progression
30%
Testing Strategy
23%
Latent Tuberculosis Infection
23%
Migrants
15%
Oxford
15%
Quality-adjusted Life Years
15%
Bacillus
15%
Induration
15%
Weak Predictors
15%
Tuberculin Skin Test
15%
Infection Surveillance
15%
Tuberculosis Burden
15%
Germany
7%
National Institute for Health Research
7%
NHS England
7%
Vaccination
7%
Cost-effectiveness
7%
Prognostic Value
7%
Prospective Cohort Study
7%
Screening Program
7%
Health Technology Assessment
7%
Negative Test Results
7%
Positive Check
7%
Clinical Utility
7%
Tuberculosis Diagnosis
7%
Economic Analysis
7%
Annual Incidence
7%
Incidence Rate
7%
General Practice Setting
7%
Performance Prediction
7%
Western European Countries
7%
Screening Strategy
7%
Community Setting
7%
Implications for Future
7%
Assessment Programs
7%
Cost-effective Approach
7%
Limited Ability
7%
Implications for Practice
7%
Two-step Approach
7%
General Community
7%
In-tube
7%
Public Health England
7%
Current Test
7%
Tuberculosis Incidence
7%
Incremental Net Benefit
7%
Tuberculosis Control Programme
7%
New Entrants
7%
Combination Strategy
7%
Cost-effective Testing
7%
Benefit Evaluation
7%
QuantiFERON
7%
Dual Test
7%
Non-progression
7%
Earth and Planetary Sciences
United Kingdom
100%
SPOT
100%
Interferon
100%
England
22%
Germany
11%
Technology Assessment
11%
Nursing and Health Professions
Interferon Gamma Release Assay
100%
Mycobacterium Tuberculosis Test Kit
100%
Tuberculin Test
33%
Quality Adjusted Life Year
22%
General Practice
11%
Cost Effectiveness Analysis
11%
Biomedical Technology Assessment
11%
Economic Analysis
11%
Rate Ratio
11%
Prospective Cohort Study
11%
Latent Tuberculosis
11%
Tuberculosis Control
11%
Psychology
Public Health
100%
Clinical Utility
100%
Technology Assessment
100%
Medicine and Dentistry
Interferon Gamma Release Assay
100%
Health Care Cost
55%
Mantoux Test
33%
Quality Adjusted Life Year
22%
General Medicine
11%
Public Health
11%
Cost-Effectiveness Analysis
11%
Technology Assessment
11%
Health Technology
11%
Prospective Cohort Study
11%
Latent Tuberculosis
11%
QuantiFERON
11%